Details for Patent: 8,501,760

Which drugs does patent 8,501,760 protect, and when does it expire?

Patent 8,501,760 protects TASIGNA and is included in one NDA.

Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-one patent family members in thirty-four countries.

Summary for Patent: 8,501,760

Title:	Pharmaceutical compositions comprising nilotinib or its salt
Abstract:	A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.
Inventor(s):	Bruneau; Nathalie (Cran-Gevrier, FR)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/624,354
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,501,760
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 8,501,760

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018		RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010		RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,501,760

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	06121371	Sep 27, 2006

International Family Members for US Patent 8,501,760

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	062980
Australia	2007301977
Brazil	PI0719438
Canada	2662571
Chile	2007002766
China	101516344